compounded retatrutide for weight loss: Study shows 30% body weight loss Lilly Prepares for Retatrutide FDA

Mollan SP, Aguiar M, Evison F, Frew E, Sinclair AJ

Together, these studies offer valuable new evidence supporting the use of GLP-1 receptor agonists for kidney and cardiovascular protection in individuals at risk for or with established chronic kidney disease

[DOI] [PubMed] [Google Scholar] 60.Yue W, et al

A BMI-23 policy means Eden will treat the woman whose scale says 28 but whose waist, blood pressure, and glucose say 35

In addition to questions about blood clotting, GLP-1s can cause side effects that may be challenging for people with hemophilia

Research presented at the American Academy of Orthopaedic Surgeons meeting in March 2026 linked GLP-1 use to nearly double the risk of bone density issues over five years